Avadel Pharmaceuticals to Speak at Investor Conferences

Dublin, May 30, 2024 – Avadel Pharmaceuticals (Nasdaq: AVDL), a biopharmaceutical company dedicated to innovating medications for improved patient outcomes, has announced its participation in several upcoming investor conferences. The company’s management team will be engaging with investors and stakeholders at these significant events.

The first engagement will be at the Jefferies Global Healthcare Conference, where a fireside chat has been scheduled for Thursday, June 6, at 10:30 a.m. ET. Following this, Avadel’s team will also present at the Goldman Sachs 45th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 12, at 3:20 p.m. ET.

For those unable to attend in person, Avadel Pharmaceuticals has made provisions to ensure accessibility. Both events will be broadcasted live via a webcast, and recordings will be archived on the company’s Investor Relations website for a duration of 90 days following each conference.

Avadel Pharmaceuticals plc, traded on Nasdaq under the ticker AVDL, is at the forefront of biopharmaceutical innovation. The company is committed to developing transformative medications that significantly improve the lives of patients. Their commercial product, LUMRYZ™, has achieved notable recognition, being the first and only once-at-bedtime oxybate approved by the U.S. Food & Drug Administration (FDA). LUMRYZ™ addresses cataplexy and excessive daytime sleepiness (EDS) in adults suffering from narcolepsy, providing a critical treatment option for these patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!